|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
Inactive Indication- |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Pilot Study on Safety and Explorative Efficacy of MD05 in Comparison With Open Flap Debridement in Patients Undergoing Periodontal Surgery to Treat Deep Intrabony Defects
The purpose of the study is to gain experience of safety and efficacy with MD05 in man in alveolar bone regeneration.
/ Not yet recruitingNot Applicable Pilot Study on Safety and explorative Efficacy of MD05 in Comparison with the Medical Device Beta-TCP Mixed with Autogenous Bone Material in Patients Undergoing Two-Stage Unilateral Maxillary Sinus Floor Augmentation - Sinus Lift Study
Pilot Study on Safety and Efficacy of MD05 in Comparison With Beta-TCP in Patients Undergoing Sinus Floor Augmentation
The primary objective is the area of newly formed bone (%) as assessed by histomorphometry with either MD05 or beta-TCP.
100 Clinical Results associated with BioNet Pharma GmbH
0 Patents (Medical) associated with BioNet Pharma GmbH
100 Deals associated with BioNet Pharma GmbH
100 Translational Medicine associated with BioNet Pharma GmbH